Alzheon hoped testing its drug in a genetically defined subgroup of Alzheimer’s disease patients would succeed, overcoming earlier clinical trial failures. Instead, preliminary results show the pill failed to outdistance a placebo.
The post Alzheon’s Precision Medicine Approach to Resurrect an Alzheimer’s Drug Fails Pivotal Study appeared first on MedCity News.
